These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12566067)

  • 1. Icodextrin-induced lipid peroxidation disrupts the mesothelial cell cycle engine.
    Gotloib L; Wajsbrot V; Shostak A
    Free Radic Biol Med; 2003 Feb; 34(4):419-28. PubMed ID: 12566067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelial dysplastic changes and lipid peroxidation induced by 7.5% icodextrin.
    Gotloib L; Wajsbrot V; Shostak A
    Nephron; 2002 Sep; 92(1):142-55. PubMed ID: 12187097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osmotic agents hamper mesothelial repopulation as seen in the doughnut in vivo model.
    Gotloib L; Wajsbrot V; Shostak A
    Perit Dial Int; 2005 Feb; 25 Suppl 3():S26-30. PubMed ID: 16048251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe peritoneal mononucleosis associated with icodextrin use in continuous ambulatory peritoneal dialysis.
    Martín J; Sansone G; Cirugeda A; Sánchez-Tomero JA; Muñoz C; Selgas R
    Adv Perit Dial; 2003; 19():191-4. PubMed ID: 14763060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe cutaneous hypersensitivity to icodextrin in a continuous ambulatory peritoneal dialysis patient.
    Lee SH; Park HC; Sim SR; Chung SJ; Kim KJ; Park WI; Hong SW; Ha SK
    J Nephrol; 2006; 19(5):673-6. PubMed ID: 17136700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation.
    Yamaguchi N; Miyamoto K; Murata T; Ishikawa E; Horiuchi T
    Artif Organs; 2016 Aug; 40(8):E158-66. PubMed ID: 27530675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of icodextrin on integrin-mediated wound healing of peritoneal mesothelial cells.
    Matsumoto M; Tamura M; Miyamoto T; Furuno Y; Kabashima N; Serino R; Shibata T; Kanegae K; Takeuchi M; Abe H; Okazaki M; Otsuji Y
    Life Sci; 2012 Jun; 90(23-24):917-23. PubMed ID: 22564410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of icodextrin- and glucose-based peritoneal dialysis fluids in their acute and chronic effects on human peritoneal mesothelial cells.
    Bender TO; Witowski J; Ksiazek K; Jörres A
    Int J Artif Organs; 2007 Dec; 30(12):1075-82. PubMed ID: 18203069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-based peritoneal dialysis fluids downregulate toll-like receptors and trigger hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells.
    Wu J; Yang X; Zhang YF; Wang YN; Liu M; Dong XQ; Fan JJ; Yu XQ
    Clin Vaccine Immunol; 2010 May; 17(5):757-63. PubMed ID: 20200188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icodextrin: an alternative peritoneal dialysis fluid.
    Chhabra D; Nash K
    Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1455-64. PubMed ID: 18950286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biocompatibility of icodextrin.
    Cooker LA; Holmes CJ; Hoff CM
    Kidney Int Suppl; 2002 Oct; (81):S34-45. PubMed ID: 12230480
    [No Abstract]   [Full Text] [Related]  

  • 12. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
    Parikova A; Zweers MM; Struijk DG; Krediet RT
    Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Icodextrin: What arguments for and against its use as an osmotic agent in peritoneal dialysis].
    Savenkoff B; Flechon-Meibody F; Goffin É
    Nephrol Ther; 2018 Jun; 14(4):201-206. PubMed ID: 29291942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis.
    Babazono T; Nakamoto H; Kasai K; Kuriyama S; Sugimoto T; Nakayama M; Hamada C; Furuya R; Hasegawa H; Kasahara M; Moriishi M; Tomo T; Miyazaki M; Sato M; Yorioka N; Kawaguchi Y;
    Am J Nephrol; 2007; 27(4):409-15. PubMed ID: 17622748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of cell death during peritoneal dialysis. A role for osmotic and oxidative stress.
    Gotloib L
    Contrib Nephrol; 2009; 163():35-44. PubMed ID: 19494593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-based PD solution, but not icodextrin-based PD solution, induces plasminogen activator inhibitor-1 and tissue-type plasminogen activator in human peritoneal mesothelial cells via ERK1/2.
    Katsutani M; Ito T; Masaki T; Kohno N; Yorioka N
    Ther Apher Dial; 2007 Apr; 11(2):94-100. PubMed ID: 17381529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new form of acute adverse reaction to icodextrin in a peritoneal dialysis patient.
    Del Rosso G; Di Liberato L; Perilli A; Cappelli P; Bonomini M
    Nephrol Dial Transplant; 2000 Jun; 15(6):927-8. PubMed ID: 10831669
    [No Abstract]   [Full Text] [Related]  

  • 18. Icodextrin: a review of its use in peritoneal dialysis.
    Frampton JE; Plosker GL
    Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to the peptidoglycan contaminant in icodextrin may cause sensitization of the patient maintained on peritoneal dialysis.
    Povlsen JV; Ivarsen P; Jørgensen KA; Madsen S
    Perit Dial Int; 2003; 23(5):509-10. PubMed ID: 14604210
    [No Abstract]   [Full Text] [Related]  

  • 20. The mesothelium under the siege of dialysis solutions: old glucose, new glucose, and glucose-free osmotic agents.
    Gotloib L
    Adv Perit Dial; 2009; 25():6-10. PubMed ID: 19886309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.